Martin Aringer

Martin Aringer's AcademicInfluence.com Rankings

Martin Aringer

Physics

#7337

World Rank

#9359

Historical Rank

physics Degrees

Download Badge

Physics

Martin Aringer's Degrees

PhD Physics University of Vienna
Masters Physics University of Vienna
Bachelors Physics University of Vienna

Why Is Martin Aringer Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Martin Aringer's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update (2010) (2474)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update (2020) (1453)
Germline Mutations in the Extracellular Domains of the 55 kDa TNF Receptor, TNFR1, Define a Family of Dominantly Inherited Autoinflammatory Syndromes (1999) (1254)
Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force (2015) (1155)
2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus (2019) (936)
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus (2019) (934)
Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis (2012) (885)
Trial of Tocilizumab in Giant‐Cell Arteritis (2017) (798)
SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout (2008) (728)
EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs (2010) (595)
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force (2014) (526)
2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus (2019) (419)
The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. (2000) (388)
European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies (2009) (356)
Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. (2004) (344)
2019 Update of the Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA–EDTA) recommendations for the management of lupus nephritis (2020) (308)
A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS) (2016) (259)
The central role of T cells in rheumatoid arthritis. (2007) (248)
Inhibition of Th1 Immune Response by Glucocorticoids: Dexamethasone Selectively Inhibits IL-12-Induced Stat4 Phosphorylation in T Lymphocytes1 (2000) (243)
Ultrasound therapy for calcific tendinitis of the shoulder. (1999) (240)
Role of interleukin‐6 in stress, sleep, and fatigue (2012) (223)
Stat4 Is Expressed in Activated Peripheral Blood Monocytes, Dendritic Cells, and Macrophages at Sites of Th1-Mediated Inflammation1 (2000) (198)
Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID) (2011) (189)
Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. (2009) (185)
Defective removal of ribonucleotides from DNA promotes systemic autoimmunity. (2015) (172)
Improvement of physical fitness and muscle strength in polymyositis/dermatomyositis patients by a training programme. (1998) (166)
The role of tumor necrosis factor-alpha in systemic lupus erythematosus (2008) (164)
Atopic dermatitis is associated with an increased risk for rheumatoid arthritis and inflammatory bowel disease, and a decreased risk for type 1 diabetes. (2016) (159)
Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs (2016) (142)
European consensus statement on the terminology used in the management of lupus glomerulonephritis (2009) (137)
Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention (2004) (136)
Performance of Antinuclear Antibodies for Classifying Systemic Lupus Erythematosus: A Systematic Literature Review and Meta‐Regression of Diagnostic Data (2018) (121)
Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus. (2007) (117)
Increased bioactive TNF in human systemic lupus erythematosus: associations with cell death (2002) (115)
The EUSTAR model for teaching and implementing the modified Rodnan skin score in systemic sclerosis (2007) (115)
Cytokine expression in lupus kidneys (2005) (114)
"To be or not to be," ten years after: evidence for mixed connective tissue disease as a distinct entity. (2012) (113)
High levels of bcl-2 protein in circulating T lymphocytes, but not B lymphocytes, of patients with systemic lupus erythematosus. (1994) (107)
Therapeutic blockade of TNF in patients with SLE-promising or crazy? (2012) (107)
Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formation. (2002) (107)
SLE - Complex cytokine effects in a complex autoimmune disease: tumor necrosis factor in systemic lupus erythematosus (2003) (104)
New treatments for SLE: cell-depleting and anti-cytokine therapies. (2005) (101)
Serum interleukin-15 is elevated in systemic lupus erythematosus. (2001) (100)
Gout--current diagnosis and treatment. (2009) (96)
How Do Patients With Newly Diagnosed Systemic Lupus Erythematosus Present? A Multicenter Cohort of Early Systemic Lupus Erythematosus to Inform the Development of New Classification Criteria (2018) (94)
Impact of sonography in gouty arthritis: comparison with conventional radiography, clinical examination, and laboratory findings. (2007) (92)
Developing and Refining New Candidate Criteria for Systemic Lupus Erythematosus Classification: An International Collaboration (2018) (88)
Activation of the interferon-gamma signaling pathway in systemic lupus erythematosus peripheral blood mononuclear cells. (2009) (87)
Current state of evidence on ‘off-label’ therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland – a consensus report (2012) (81)
Janus kinases and their role in growth and disease. (1999) (81)
Prevalence and clinical associations of anti-Ku antibodies in patients with systemic sclerosis: a European EUSTAR-initiated multi-centre case–control study (2007) (79)
Development of quality indicators to evaluate the monitoring of SLE patients in routine clinical practice. (2011) (78)
Severe infections in plasmapheresis-treated systemic lupus erythematosus. (1998) (77)
Toward new criteria for systemic lupus erythematosus—a standpoint (2016) (76)
Does mixed connective tissue disease exist? Yes. (2005) (75)
Low risk of renal flares and negative outcomes in women with lupus nephritis conceiving after switching from mycophenolate mofetil to azathioprine. (2013) (73)
Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) – results from a nationwide cohort in Germany (GRAID) (2013) (72)
As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout (2013) (72)
Listeria-Associated Arthritis in a Patient Undergoing Etanercept Therapy: Case Report and Review of the Literature (2005) (71)
Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population. (2014) (70)
Inflammatory markers in systemic lupus erythematosus. (2019) (67)
Concepts important to persons with systemic lupus erythematosus and their coverage by standard measures of disease activity and health status. (2007) (66)
IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational study (2005) (65)
Glucocorticoid Dosages and Acute‐Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab (2019) (64)
Performance of the 2011 ACR/EULAR preliminary remission criteria compared with DAS28 remission in unselected patients with rheumatoid arthritis (2012) (64)
Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis (2019) (59)
Cancer polyarthritis resembling rheumatoid arthritis as a first sign of hidden neoplasms. Report of two cases and review of the literature. (2001) (55)
Effects of 17 beta-estradiol on circulating adhesion molecules. (1994) (54)
2021 DORIS definition of remission in SLE: final recommendations from an international task force (2021) (53)
Early symptoms of systemic lupus erythematosus (SLE) recalled by 339 SLE patients (2018) (50)
Cytokine regulation of apoptosis and Bcl-2 expression in lymphocytes of patients with systemic lupus erythematosus (2000) (49)
Identification of relevant concepts of functioning in daily life in people with systemic lupus erythematosus: A patient Delphi exercise. (2008) (47)
EULAR/ACR classification criteria for SLE. (2019) (47)
High turnover bone disease following lung transplantation. (1998) (45)
Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus (2019) (45)
Photopheresis treatment enhances CD95 (fas) expression in circulating lymphocytes of patients with systemic sclerosis and induces apoptosis. (1997) (45)
Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria (2018) (44)
Indication Criteria for Total Knee Arthroplasty in Patients with Osteoarthritis – A Multi-perspective Consensus Study Indikationskriterien für den endoprothetischen Gelenkersatz bei Gonarthrose – eine multiperspektivische Konsensstudie (2017) (44)
Time of Disease‐Modifying Antirheumatic Drug Start in Juvenile Idiopathic Arthritis and the Likelihood of a Drug‐Free Remission in Young Adulthood (2019) (43)
Potential benefit of convalescent plasma transfusions in immunocompromised patients with COVID-19 (2021) (41)
Multicenter Delphi Exercise to Identify Important Key Items for Classifying Systemic Lupus Erythematosus (2018) (41)
Increased transendothelial migration of scleroderma lymphocytes (2004) (40)
Anti-cytokine therapy in systemic lupus erythematosus (2005) (40)
Differential expression of the protooncogene bcl-2 in normal and osteoarthritic human articular cartilage. (1995) (39)
Efficacy and Safety of Rituximab Treatment in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitides: Results from a German Registry (GRAID) (2012) (37)
Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database (2018) (36)
Classifying and diagnosing systemic lupus erythematosus in the 21st century (2020) (34)
Derangement of apoptosis-related lymphocyte homeostasis in systemic sclerosis. (2000) (34)
Expression of adhesion molecules on synovial fluid and peripheral blood monocytes in patients with inflammatory joint disease and osteoarthritis (1999) (33)
ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisis—a EUSTAR analysis (2020) (33)
Interferon signals and monocytic sensitization of the interferon-γ signaling pathway in the peripheral blood of patients with rheumatoid arthritis. (2012) (33)
Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosus. (2008) (32)
Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities (2020) (32)
Leflunomide inhibits transendothelial migration of peripheral blood mononuclear cells (2004) (32)
Innate immune processes in lupus erythematosus. (2013) (31)
The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone (2017) (31)
Mixed connective tissue disease: what is behind the curtain? (2007) (30)
Validation of Standardized Questionnaires Evaluating Symptoms of Depression in Rheumatoid Arthritis Patients: Approaches to Screening for a Frequent Yet Underrated Challenge (2017) (30)
New Criteria for Lupus (2020) (30)
Characterisation of cellular and humoral autoimmune responses to histone H1 and core histones in human systemic lupus erythaematosus (2008) (29)
Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial (2021) (28)
Increased levels of circulating intercellular adhesion molecule-1 in patients with systemic sclerosis. (1994) (28)
Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteria (2011) (27)
ICF Core Sets: how to specify impairment and function in systemic lupus erythematosus (2006) (26)
EUSTAR biobanking: recommendations for the collection, storage and distribution of biospecimens in scleroderma research (2011) (26)
Associations Between Classification Criteria Items in Systemic Lupus Erythematosus (2020) (26)
New insights into the prevalence of depressive symptoms and depression in rheumatoid arthritis – Implications from the prospective multicenter VADERA II study (2019) (25)
Response to: ‘European League against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus: the laboratory immunologist's point of view’ by Infantino et al (2019) (25)
European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance (2021) (25)
OP0020 Validation of new systemic lupus erythematosus classification criteria (2018) (24)
Periodic fever syndromes--a clinical overview. (2004) (24)
Characterization and Analysis of the Proximal Janus Kinase 3 Promoter1 (2003) (24)
Immunoadsorption in Autoimmune Diseases Affecting the Kidney. (2017) (23)
Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosus (2008) (22)
A 3-Day Delay in Synovial Fluid Crystal Identification Did Not Hinder the Reliable Detection of Monosodium Urate and Calcium Pyrophosphate Crystals (2013) (22)
Immunoadsorption for connective tissue disease. (2013) (22)
Delayed diagnosis adversely affects outcome in systemic lupus erythematosus: Cross sectional analysis of the LuLa cohort (2021) (22)
OP0140 LONG-TERM OUTCOME OF TOCILIZUMAB FOR PATIENTS WITH GIANT CELL ARTERITIS: RESULTS FROM PART 2 OF THE GIACTA TRIAL (2019) (21)
Nintedanib in Patients With Autoimmune Disease–Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial (2022) (21)
The development of a simple questionnaire to screen patients with SLE for the presence of neuropsychiatric symptoms in routine clinical practice (2011) (21)
Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial (2018) (20)
Use of methotrexate in patients with systemic lupus erythematosus and primary Sjögren's syndrome. (2010) (20)
Immunoadsorption (IAS) as a rescue therapy in SLE: considerations on safety and efficacy. (2004) (19)
T lymphocyte activation--an inside overview. (2002) (19)
TNF inhibition in SLE: where do we stand? (2009) (19)
International cohort study of 73 anti-Ku-positive patients: association of p70/p80 anti-Ku antibodies with joint/bone features and differentiation of disease populations by using principal-components analysis (2012) (18)
Immunoadsorption as a rescue therapy in systemic lupus erythematosus: considerations on safety and efficacy (2004) (18)
Understanding deficient elimination of uric acid (2008) (18)
A Bridge Between Interferon-α and Tumor Necrosis Factor in Lupus (2008) (17)
[The S2k guideline: Indications for knee endoprosthesis : Evidence and consent-based indications for total knee arthroplasty]. (2018) (17)
Destructive lymphadenopathy and T-lymphocyte activation in adult-onset Still's disease. (1995) (16)
The Janus faces of allopurinol-allopurinol hypersensitivity syndrome. (2008) (16)
Response to: ‘‘2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus’ by Aringer et al’ by Cui et al (2020) (15)
Effect of Nintedanib on Lung Function in Patients With Systemic Sclerosis−Associated Interstitial Lung Disease: Further Analyses of a Randomized, Double‐Blind, Placebo‐Controlled Trial (2020) (14)
Autoimmunity and rheumatoid arthritis. (2004) (14)
Lots of autoantibodies equal lupus? (2013) (13)
Faculty Opinions recommendation of Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. (2009) (13)
Engineering Anticancer T Cells for Extended Functional Longevity (2004) (12)
Role of tumor necrosis factor alpha and potential benefit of tumor necrosis factor blockade treatment in systemic lupus erythematosus: comment on the editorial by Pisetsky. (2001) (12)
Immunoadsorption Followed by Rituximab as a Definitive Treatment for Insulin Autoimmune Syndrome (Hirata Syndrome): A Case Report (2017) (12)
[Rheumatology - Integration into student training (RISA) : Current structure of clinical rheumatology in German universities (RISA III)]. (2016) (11)
Withdrawal of therapy in non-renal systemic lupus erythematosus: is this an achievable goal? (2013) (11)
New classification criteria for systemic lupus erythematosus (2020) (11)
Tocilizumab in the treatment of giant cell arteritis. (2018) (10)
[Molecular basis of primary renal hyperuricemia : role of the human urate transporter hURAT1]. (2007) (10)
A bridge between interferon-alpha and tumor necrosis factor in lupus. (2008) (10)
Lokale und systemische Knocheneffekte bei rheumatoider Arthritis (2012) (10)
Rheumatologie – Integration in die studentische Ausbildung (RISA) (2016) (10)
Safety of off-label biologicals in systemic lupus erythematosus (2015) (10)
Association of Dendritic Cell Signatures With Autoimmune Inflammation Revealed by Single‐Cell Profiling (2019) (10)
Immunoadsorption for systemic lupus erythematosus. (2009) (10)
Vaccination under TNF blockade - less effective, but worthwhile (2012) (10)
OP0064 Joint EULAR/ERA-EDTA recommendations for the management of adult and pediatric lupus nephritis (2013) (9)
[Standards of care for people with rheumatoid arthritis in Europe : Translation and comments of the eumusc.net recommendations supported by EULAR performed by a national task force of the professional organisations DGRh and VRA supported by "Deutsche Rheumaliga"]. (2016) (9)
Befragung von Rheumatologen in Sachsen, Sachsen-Anhalt und Thüringen zu Weiterbildungstätigkeit und beruflicher Situation: Kein Ausweg aus der rheumatologischen Unterversorgung (2019) (9)
Autoantibodies to the translational suppressors T cell intracytoplasmic antigen 1 and T cell intracytoplasmic antigen 1-related protein in patients with rheumatic diseases: increased prevalence in systemic lupus erythematosus and systemic sclerosis and correlation with clinical features. (2008) (9)
Long-Term Outcome of Tocilizumab for Patients with Giant Cell Arteritis: Results from Part 2 of a Randomized Controlled Phase 3 Trial (2019) (9)
Tophaceous Gout and Renal Insufficiency: A New Solution for an Old Therapeutic Dilemma (2011) (9)
Improvement of cutaneous inflammation and panniculitis in patients with dermatomyositis by the Janus kinase inhibitor baricitinib (2022) (8)
[Statement on the use of mycophenolate mofetil for systemic lupus erythematosus]. (2013) (8)
[Recipes systemic lupus erythematosus]. (2014) (8)
Relevant incidence of cervical arthritis in patients with erosive seropositive rheumatoid arthritis even today. (2013) (8)
TNF-alpha blockade with infliximab in a patient with lupus erythematosus profundus. (2012) (8)
Engulfed cell remnants, and not cells undergoing apoptosis, constitute the LE-cell phenomenon (2007) (8)
Rheumatologin/Rheumatologe in spe: Wie geht es weiter? (2019) (8)
[Management of systemic lupus erythematosus]. (2016) (8)
Parvovirus infection in early arthritis. (2016) (7)
Gicht@@@Gouty arthritis (2016) (7)
Incidence and risk factors for gangrene in patients with systemic sclerosis from the EUSTAR cohort. (2019) (7)
InflammationMacrophages at Sites of Th1-Mediated Blood Monocytes, Dendritic Cells, and Stat4 Is Expressed in Activated Peripheral (2000) (7)
Systemic sclerosis phase III clinical trials: Hope on the horizon? (2018) (7)
Mixed lymphohematopoietic chimerism and response in Wegener's granulomatosis. (2010) (7)
Treat to Target in Systemic Lupus Erythematosus. (2019) (7)
Classification of systemic lupus erythematosus in children and adults (2022) (7)
Gemeinsame deutschsprachige Nomenklatur für die systemische Sklerose (2015) (7)
Complex cytokine effects in a complex autoimmune disease : tumor necrosis factor in systemic lupus erythematosus (2015) (7)
Europäische Versorgungsstandards für Menschen mit rheumatoider Arthritis (2016) (7)
Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study) (2021) (7)
Kochrezepte Systemischer Lupus erythematodes (2014) (7)
Functional and molecular aspects of transient T cell unresponsiveness: role of selective interleukin‐2 deficiency (2003) (6)
Quality indicators for systemic lupus erythematosus based on the 2019 EULAR recommendations: development and initial validation in a cohort of 220 patients (2021) (6)
Stellungnahme zum Einsatz von Mycophenolat-Mofetil beim systemischen Lupus erythematodes (2013) (6)
Morbus Still im Kindes- und Erwachsenenalter (2017) (6)
Serum of patients with antiphospholipid syndrome induces adhesion molecules in endothelial cells. (2017) (6)
[Chondrocalcinosis due to calcium pyrophosphate deposition (CPPD). From incidental radiographic findings to CPPD crystal arthritis]. (2014) (6)
New lupus criteria: a critical view (2020) (6)
Chemosensory function is decreased in rheumatoid arthritis (2020) (6)
Systemischer Lupus erythematodes (2005) (6)
SAT0415 Performance of Anti-Nuclear Antibodies (ANA) for Classifying Systemic Lupus Erythematosus (SLE): A Systematic Literature Review and Meta-Regression of Diagnostic Data (2015) (6)
Relevant Concepts of Functioning for Patients With Systemic Lupus Erythematosus Identified in a Delphi Exercise of Experts and a Literature Review (2014) (6)
Systemic Lupus Erythematosus Classification and Diagnosis. (2021) (5)
Endpoints for randomised controlled trials in systemic lupus erythematosus. (2012) (5)
Assessing the EULAR/ACR classification criteria for patients with systemic lupus erythematosus (2022) (5)
Management des systemischen Lupus erythematodes (2016) (5)
Long term safety and efficacy of open-label infliximab for SLE (2007) (5)
Comorbidity and healthcare utilisation in persons with incident systemic lupus erythematosus followed for 3 years after diagnosis: analysis of a claims data cohort (2021) (5)
Swimming against the stream: the fishbowl discussion method as an interactive tool for medical conferences: experiences from the 11th European Lupus Meeting (2018) (5)
Systemischer Lupus erythematodes (SLE) – neue Klassifikationskriterien (2018) (5)
Effects of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) and normal versus elevated C-reactive protein (CRP) at baseline: analyses from the SENSCIS trial (2020) (5)
FRI0193 2019 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (2019) (5)
FRI0341 Do Patients with SLE at Onset Differ from Mimickers? A Comparison of Clinical and Serological Manifestations in A Multicenter Cohort To Inform The Development of New Classification Criteria for SLE (2016) (5)
[Survey of rheumatologists in Saxony, Saxony-Anhalt and Thuringia regarding the occupational situation and activities in further education: no way out of the undersupply of rheumatological care]. (2019) (5)
A glimpse into the future of systemic lupus erythematosus (2022) (5)
S2k-Leitlinie: Indikation Knieendoprothese (2018) (5)
[Common German language nomenclature for systemic sclerosis]. (2015) (5)
A chronic recurrent disease course of dermatomyositis is associated with autoantibodies against transcriptional intermediary factor 1‐γ (2017) (4)
ANA as an Entry Criterion in SLE Classification (2018) (4)
[Systemic lupus erythematosus--activity and outcome]. (2006) (4)
High disease activity of ankylosing spondylitis in the community before the introduction of tumour necrosis factor blockers (2006) (4)
Advances in SLE classification criteria. (2022) (4)
Faculty Opinions recommendation of Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials. (2017) (4)
Biologika und „small molecules“ beim systemischen Lupus erythematodes (2020) (4)
Kristallinduzierte Inflammasomaktivierung: Gicht und Pseudogicht (2009) (4)
[Still's disease in children and adults]. (2017) (4)
[Future of rheumatologists: what are the perspectives? : Survey of resident physicians in rheumatology in middle Germany]. (2019) (4)
New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension (2021) (4)
Janus kinase inhibitors clear to land: Janus kinase inhibitors in RA. (2018) (4)
Response to: ‘Do the 2019 EULAR/ACR SLE classification criteria close the door on certain groups of SLE patients?’ by Chi et al (2019) (4)
[MR imaging in gout]. (1996) (4)
Effects of cyclophosphamide and rituximab in patients with connective tissue diseases with severe interstitial lung disease. (2021) (4)
[Cytokine blockade - a promising therapeutic option in SLE]. (2008) (3)
Polyarthritiden – vom Symptom zur Diagnose (2021) (3)
[Still's disease in children and adults]. (2017) (3)
ICHIBAN, a non-interventional study evaluating tocilizumab long-term effectiveness and safety in patients with active rheumatoid arthritis. (2020) (3)
Faculty Opinions recommendation of Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. (2011) (3)
Response to: Correspondence on “European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance” by Aringer et al (2021) (3)
Biologika bei SLE (2014) (3)
Systemischer Lupus erythematodes (2011) (3)
Response to: ‘New 2019 SLE EULAR/ACR classification criteria are valid for identifying patients with SLE among patients admitted for pericardial effusion’ by Sacre et al (2019) (3)
Morbus Still im Kindes- und Erwachsenenalter (2017) (3)
POS0070 CONTINUED TREATMENT WITH NINTEDANIB IN PATIENTS WITH LIMITED CUTANEOUS SYSTEMIC SCLEROSIS (lcSSc) AND INTERSTITIAL LUNG DISEASE (ILD) (2022) (3)
Recent advances in managing systemic sclerosis (2017) (3)
Successful treatment of high turnover osteoporosis in a patient with adrenocortical insufficiency. (2000) (3)
Time to Flare in Patients with New-Onset versus Relapsing Giant Cell Arteritis Treated with Tocilizumab or Placebo Plus Prednisone Tapering : 3-Year Results from a Randomized Controlled Phase 3 Trial (2019) (3)
Myelodysplastisches Syndrom, akute Leukämie und Stammzelltransplantation (2017) (3)
Zytokinblockade – eine vielversprechende Therapieoption bei SLE (2008) (3)
Systemischer Lupus erythematodes: Aktivität und Outcome (2006) (3)
Chondrokalzinose durch Kalziumpyrophosphat-Dihydrat-Ablagerung (CPPD) (2014) (2)
OP0002 Multicriteria decision analysis for developing new classification criteria for systemic lupus erythematosus (2017) (2)
Glucocorticoid dosing and relapses in giant cell arteritis-a single center cohort study. (2021) (2)
Sonographische Gelenk- und Weichteildiagnostik bei Rheumatoider Arthritis (2002) (2)
Gibt es wirklich einen kutanen Lupus erythematodes? (2010) (2)
CHARACTERIZATION OF CELLULAR AND HUMORAL AUTOIMMUNE RESPONSES TO HISTONE H 1 AND CORE HISTONES IN HUMAN SYSTEMIC LUPUS ERYTHEMATOSUS (2008) (2)
Frühe rheumatoide Arthritis – wer schnell hilft, hilft doppelt (2007) (2)
Januskinaseinhibitoren@@@Janus kinase inhibitors (2017) (2)
[Biosimilars : Current state of the build up to series production]. (2013) (2)
[Safety and efficacy of off-label use of biologic therapies in patients with inflammatory rheumatic diseases refractory to standard of care therapy : Data from a nationwide German registry (GRAID2)]. (2018) (2)
SAT0531 Acute phase reactant levels and prednisone doses at disease flare in patients with giant cell arteritis: prospective data from the giacta trial (2018) (2)
Systemischer Lupus erythematodes (2021) (2)
Antibodies to Ribosomal P in Lupus Psychosis Resolving after Rituximab plus Cyclophosphamide – A Case Report (2013) (2)
What are the topics you care about making trials in lupus more effective? Results of an Open Space meeting of international lupus experts (2021) (2)
Open-label infliximab for systemic lupus erythernatosus: long-term follow-up of 11 patients. (2006) (2)
Kristallarthropathien – alt, aber wichtig (2007) (2)
Systemic lupus erythematosus does not prevent antibody responses to SARS-CoV-2 (2021) (2)
[Early rheumatoid arthritis--rapid help is double help]. (2007) (2)
Entwicklung von Qualitätsstandards für die Versorgung von Patient*innen mit rheumatoider Arthritis zur Anwendung in Deutschland (2021) (2)
Sicherheit und Wirksamkeitshinweise zum Off-label-Einsatz von Biologikatherapien nach Versagen konventioneller Therapien bei Patienten mit entzündlich rheumatischen Erkrankungen (2018) (2)
Effector Mechanisms in Autoimmunity (2020) (2)
Response to: ‘Do 2019 European League against rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus also indicate the disease activity?’ by Teng et al (2020) (2)
Treating rheumatoid arthritis with new disease modifying drugs. (2002) (2)
Molekulare Grundlagen der primär-renalen Hyperurikämie (2007) (2)
Inflammasom und Gicht (2016) (2)
[Lupus erythematosus - Update 2016]. (2016) (2)
272 Acute phase reactant levels and prednisone doses at disease flare in patients with giant cell arteritis: prospective data from the GiACTA trial (2019) (2)
Response to: ‘Correspondence on ‘Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities’’ by Rönnelid et al (2020) (2)
[Crystal-induced activation of the inflammasome: gout and pseudogout]. (2009) (2)
[Rheumatoid arthritis today]. (2008) (2)
Response to: ‘Role of ANA testing in the classification of patients with systemic lupus erythematosus’ by Pisetsky et al (2019) (1)
[Mission statement from rheumatologists in the German Society of Rheumatology (DGRh e. V.) : We live rheumatology. German version]. (2020) (1)
Deletion 13q14 in Plasma Cells of a Patient with Lupus Erythematosus and Autoimmune Hepatitis (2014) (1)
European League Against Rheumatism (EULAR) recommendations and EULAR/American College of Rheumatology criteria-documenting progress in lupus. (2020) (1)
Factors detrimental to work productivity and daily activities in systemic lupus erythematosus patients – Analysis of the German LuLa study (2021) (1)
Defective removal of ribonucleotides from DNA promotes systemic lupus erythematosus (2015) (1)
Lung Function Decline in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) by Time Since First Non-Raynaud Symptom: Subgroup Analysis of the SENSCIS Trial (2020) (1)
Reply (2020) (1)
[Immunology of systemic inflammatory diseases]. (2018) (1)
Clinical and immunological effects of anti-TNF therapy in systemic lupus erythematosus (SLE) (2003) (1)
Evaluation of the EULAR/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in a Population‐Based Registry (2022) (1)
Multiparametric Analysis of Connective Tissue Disease Specific Autoantibodies Using a Spot Immunoassay. (2019) (1)
OP0131 Optimal dose of tocilizumab for the treatment of giant cell arteritis: efficacy, safety, and exposure-efficacy analysis from giacta (2017) (1)
Mission statement from rheumatologists in the German Society of Rheumatology (DGRh e. V.) (2020) (1)
Response to: ‘New 2019 SLE EULAR/ACR classification criteria are valuable for distinguishing patients with SLE from patients with pSS’ by Assan et al (2019) (1)
Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database (2019) (1)
Relevance of immunomodulatory therapy for interstitial lung disease in systemic sclerosis. (2021) (1)
Getting scientists together: the ACR/EULAR exchange programme (2003) (1)
[Does cutaneous lupus erythematodes really exist?]. (2010) (1)
Reply (2019) (1)
FRI0151 COMORBIDITY IN INCIDENT SYSTEMIC LUPUS ERYTHEMATOSUS: ANALYSIS OF A CLAIMS DATA COHORT (2020) (1)
AB0430 Leflunomide as a second line dmard after methotrexate has limited impact on rheumatoid arthritis in real life (2017) (1)
Efficacy and safety of tocilizumab in patient subgroups with new-onset and relapsing giant cell arteritis from a randomized, double-blind, placebo-controlled, phase 3 trial (2017) (1)
Chilblain Lupus Erythematosus (2014) (1)
THU0158 IMPAIRED OLFACTORY FUNCTION IN PATIENTS WITH RHEUMATOID ARTHRITIS (2019) (1)
The safety and effectiveness of tocilizumab in elderly patients with rheumatoid arthritis and in patients with comorbidities associated with age (2021) (1)
Faculty Opinions recommendation of Current Approaches to the Treatment of Systemic-Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH). (2017) (1)
[Development of quality standards for patients with rheumatoid arthritis for use in Germany]. (2021) (1)
[Modern drug therapy for systemic sclerosis associated interstitial lung disease]. (2021) (1)
THU0189 EFFICACY AND SAFETY OF NINTEDANIB IN PATIENTS WITH AUTOIMMUNE DISEASE-RELATED INTERSTITIAL LUNG DISEASE TREATED WITH DMARDS AND/OR GLUCOCORTICOIDS AT BASELINE (2020) (1)
OP0128 SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE CHARACTERISTICS ASSOCIATED WITH THE TYPE I INTERFERON GENE SIGNATURE: BASELINE DATA OF THE SLE PROSPECTIVE OBSERVATIONAL COHORT STUDY (SPOCS) (2019) (1)
Stat1 and phosphorylated Stat1 are increased in lymphocytes and monocytes of patients with systemic lupus erythematosus (2005) (1)
AB0396 Tocilizumab i.v. effectiveness in ra patients is independent of smoking status (2017) (1)
Cytokines and Joint Injury. Edited by W. B. van den Berg and P. Miossec. €149.80. Birkhäuser, Basel-Boston-Berlin, 2004. 296 pp. ISBN 3-7643-7001-7. (2004) (1)
[Tapering and termination of immunosuppressive therapy : Systemic lupus erythematosus]. (2017) (1)
Lupus erythematodes – Update 2016 (2016) (1)
FRI0217 Impact of rituximab in combination with leflunomide and rituximab retreatment with two different dosages on patient-reported outcomes: results from a multicenter randomized placebo controlled investigator initiated clinical trial in active rheumatoid arthritis (AMARA-STUDY) (2017) (1)
[AV-block II and arthritis as manifestations of Lyme borreliosis]. (1995) (1)
Frauen und Gicht – eine diagnostische Herausforderung Gout in Women – a Diagnostic Challenge (2020) (1)
Systemerkrankung rheumatoide Arthritis (2012) (1)
Anifrolumab für die Therapie des systemischen Lupus erythematodes (2022) (1)
MR-Bildgebung bei der Gicht (1996) (1)
Rheumatologie 2021 (2021) (1)
Cyclooxygenase-2-selektive Rheumaschmerzmittel (2003) (1)
Gicht (2022) (1)
Osteopathien nach Lungentransplantation (1999) (1)
Diabetes und Rheuma – Interaktionen und Auswirkungen auf die Therapie (2014) (1)
Ausschleichen und Beenden von immunsuppressiven Therapien (2017) (1)
Systemerkrankungen – Fit für 2020! (2019) (1)
Faculty Opinions recommendation of The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis. (2008) (0)
Faculty Opinions recommendation of Selexipag for the treatment of pulmonary arterial hypertension. (2017) (0)
Infliximab-Behandlung einer Patientin mit Lupus erythematodes profundus (2011) (0)
Regulatory T cells have anti-inflammatory effects by diluting TNF (2008) (0)
OP0098 The jak3 promoter region is stimulated by t cell activation and contains essential ap-1 and ets-1 elements (2001) (0)
[Genitourinary malignancies and rheumatoid arthritis]. (2016) (0)
Faculty Opinions recommendation of Effect of nintedanib in subgroups of idiopathic pulmonary fibrosis by diagnostic criteria. (2017) (0)
Predictors of Early Bone Erosion in Patients With Synovitis of Recent Onset (1999) (0)
Essential and Optional Drugs for Rheumatic Diseases (2018) (0)
PS2:44 Role of anti-dfs70 antibodies in the serological diagnostics of sle (2018) (0)
[Anifrolumab in the treatment of systemic lupus erythematosus]. (2022) (0)
Skin Manifestations of Systemic Lupus Erythematosus (2014) (0)
SAT0193 Ra patients with inflammatory anemia benefit from increased hemoglobin and decreased fatigue under tocilizumab therapy (2017) (0)
POS0605 IN PATIENTS WITH RHEUMATOID ARTHRITIS, CLINICAL EXAMINATION OF THE FEET IS IMPORTANT FOR UNDERSTANDING INDIVIDUAL DISEASE BURDEN, BUT DOES NOT PROVOKE A CHANGE IN THERAPY IN MOST CASES (2022) (0)
POS0731 ASSOCIATION OF PATIENT-REPORTED OUTCOMES WITH TYPE I INTERFERON GENE SIGNATURE FROM THE INTERNATIONAL SYSTEMIC LUPUS ERYTHEMATOSUS PROSPECTIVE OBSERVATIONAL COHORT STUDY (SPOCS) (2022) (0)
Chondrocalcinosis and Pseudogout - More Relevant than Ever (2008) (0)
14 – Signal transduction in immune cells (2015) (0)
Faculty Opinions recommendation of Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction. (2012) (0)
Impaired T-cell rsponse to subsequent TCR-stimulation after anti-CD3 induced proliferation (2001) (0)
List of Contributors (2020) (0)
Anti-TNF-Therapie des Morbus Bechterew (2004) (0)
Erratum to: Glucocorticoid dosing and relapses in giant cell arteritis-a single centre cohort study. (2021) (0)
FRI0207 Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate, methotrexate alone or placebo: the dinora trial (2017) (0)
Safety aspects and long term efficacy of TNF blockade with infliximab in patients with systemic lupus erythematosus (2008) (0)
Enhanced transendothelial in vitro migration of scleroderma lymphocytes (2001) (0)
Effectiveness of Different Rituximab Doses Combined with Leflunomide in the Treatment or Retreatment of Rheumatoid Arthritis: Part 2 of a Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA) (2022) (0)
Reply (2020) (0)
Sustained effectiveness and safety of subcutaneous tocilizumab over two years in the ARATA observational study. (2022) (0)
Decreased interleukin-6 receptor (IL-6Rα) and increased signal transducer and activator of transcription 3 (Stat3) phosphorylation in rheumatoid arthritis (RA) are reversed by IL-6Rα blockade (2012) (0)
AB0270 Treatment response to rituximab in combination with leflunomide is influenced by anticcp status in active rheumatoid arthritis: results from a multicenter randomised placebo-controlled investigator initiated clinical trial in active rheumatoid arthritis (AMARA-STUDY) (2018) (0)
Response to: ‘Development and initial validation of diagnostic gene signatures for systemic lupus erythematosus’ by Wang et al (2019) (0)
5. Myositiden (2019) (0)
Binding properties of anti-histone H1 antibodies suggest that nuclei of necrotic cells rather than cells undergoing apoptosis are engulfed in the LE cell phenomenon (2005) (0)
FRI0192 A SYSTEMATIC LITERATURE REVIEW TO INFORM THE 2019 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (2019) (0)
Reply (2020) (0)
Faculty of 1000 evaluation for Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial. (2018) (0)
Faculty Opinions recommendation of Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. (2013) (0)
T lymphocytes of patients with SLE lack Stat4 (2001) (0)
Faculty Opinions recommendation of Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. (2008) (0)
Autoantibody detection by arrays (2002) (0)
Is the Rheumatoid Arthritis Impact of Disease (RAID) score a meaningful instrument for other inflammatory rheumatic diseases? A cross-sectional analysis of data from the German National Database (2022) (0)
[Should HCQ be administered in SLE patients dependent on hemodialysis?] (2022) (0)
IEX-1 transgenic mice develop a lupus-like disease (2002) (0)
FRI0174 THE LONGER THE DELAY IN DIAGNOSIS, THE WORSE THE OUTCOME IN SLE – CROSS SECTIONAL ANALYSIS OF A GERMAN LONG-TERM STUDY (LULA COHORT) (2020) (0)
A10.10 Examination of IL-6, TNF I and II Receptor Distribution on Peripheral Blood Mononuclear Cells (PBMC) in Seropositive and Seronegative Rheumatoid Arthritis (RA) (2013) (0)
How Should We Consider Lupus Without Antinuclear Antibodies? (2019) (0)
SAT0163 LOW CARDIOVASCULAR EVENT RATE DURING TOCILIZUMAB TREATMENT IN THE NON-INTERVENTIONAL STUDY ICHIBAN (2019) (0)
THU0351 Current Smoking is a Risk Factor for Giant Cell Arteritis in Patients with Polymyalgia Rheumatica (2015) (0)
[Crystal-induced arthritis--old but important]. (2007) (0)
Pathogenic role of anti-myeloperoxidase ANCA (2002) (0)
POS0764 EULAR RECOMMENDATION-BASED QUALITY INDICATORS (QIS) FOR SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): ELABORATION, FINAL SET, PERFORMANCE AND INITIAL VALIDATION (2021) (0)
Rheumatoide Arthritis/chronische Polyarthritis heute (2008) (0)
[Lupus therapy on the move : The direction is right!]. (2015) (0)
Faculty Opinions recommendation of Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial. (2019) (0)
Editor's acknowledgement (2005) (0)
Faculty Opinions recommendation of Baricitinib in Patients with Refractory Rheumatoid Arthritis. (2016) (0)
Who will respond to type I interferon receptor blockade in SLE? (2022) (0)
SAT0035 Ankylosing spondylitis, psoriatic arthritis and reactive arthritis show increased bone resorption and differ with regard to bone formation (2001) (0)
Faculty Opinions recommendation of Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial. (2011) (0)
Clinical applications of IFN-α blockade in systemic lupus erythematosus (2009) (0)
POS0615 TOCILIZUMAB IS SAFE AND EFFECTIVE IN ELDERLY PATIENTS WITH RHEUMATOID ARTHRITIS (2021) (0)
Der Blick auf die Komorbiditäten zeigt auch die Versorgungsqualität (2021) (0)
T Lymphocytes Inhibits IL-12-Induced Stat 4 Phosphorylation Glucocorticoids : Dexamethasone Selectively Inhibition of Th 1 Immune Response by Frucht , (2000) (0)
POS0733 REAL-LIFE PHYSICAL ACTIVITY IN SLE PATIENTS: ASSOCIATIONS WITH FATIGUE AND QUALITY OF SLEEP (2021) (0)
Autoinflammation in der Inneren Medizin – therapeutische Konsequenzen? (2011) (0)
Neue Klassifikationskriterien des SLE: was helfen sie für die klinische Diagnose des SLE? (2020) (0)
Systemischer Lupus erythematodes: Strukturierte Diagnostik – Erfolg versprechende Therapie (2023) (0)
Rheumatoide Arthritis ausbremsen (2010) (0)
O26 Effects of baseline prednisone dose on remission and disease flare in patients with giant cell arteritis treated with tocilizumab in the GiACTA trial (2019) (0)
Verlauf der interstitiellen Lungenerkrankung bei systemischer Sklerose (2020) (0)
Rheumatologie im Medizinstudium (2020) (0)
Systemischer Lupus erythematodes – die Standards 2015 (2014) (0)
Praktikable Sjögren-Diagnostik bei interstitieller Lungenerkrankung – ein Diskussionsbeitrag (2023) (0)
OP0260 Lower Intestinal Perforations Are More Frequent and Present Untypically in Patients Treated with Tocilizumab Compared To Other Biologic or Conventional Synthetic DMARDS (2016) (0)
How should we consider Lupus without ANA? (2018) (0)
Jahrestagung der ÖGR-20. und 21. November 2009. Abstracts der Posterpräsentationen (2017) (0)
Erste EULAR-Empfehlungen (Points to Consider) für rheumatische Nebenwirkungen von Checkpoint-Inhibitoren (2022) (0)
Neue SLE-Klassifikationskriterien funktionieren bei Kindern (2023) (0)
Urologische Malignome und rheumatoide Arthritis (2016) (0)
Immunpathogenese des systemischen Lupus erythematodes (2022) (0)
Verlauf der interstitiellen Lungenerkrankung bei systemischer Sklerose (2021) (0)
[Gouty arthritis]. (2016) (0)
Die Zeitschrift für Rheumatologie dankt den Gutachtern 2012 (2012) (0)
Sensitisation of the IFNγ-Stat1-signalling-pathway in rheumatoid arthritis monocytes (2011) (0)
Faculty Opinions recommendation of An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. (2010) (0)
Faculty Opinions recommendation of Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. (2017) (0)
351. EFFECTS OF BASELINE PREDNISONE DOSE ON REMISSION AND DISEASE FLARE IN PATIENTS WITH GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB IN A PHASE 3 RANDOMIZED CONTROLLED TRIAL (2018) (0)
Biologikatherapie beim systemischen Lupus erythematodes (2015) (0)
THU0674 ANTI-DFS70 antibody – a biomarker that aid in the exclusion of ana associated rheumatic diseases (2017) (0)
THU0349 Early Symptoms of Systemic Lupus Erythematosus (SLE) Recalled by 337 SLE Patients (2016) (0)
Die Zeitschrift für Rheumatologie dankt den Gutachtern 2017 (2018) (0)
Relevance of Correct Attribution to SLE in Applying the EULAR/ACR 2019 SLE Classification Criteria. (2019) (0)
Systemischer Lupus erythematodes –die Standards 2015 (2014) (0)
Systemischer Lupus erythematodes durch Tumornekrosefaktor-Blocker – Eine seltene Nebenwirkung einer Uveitis-intermedia-Therapie (2021) (0)
Immunologie der entzündlichen Systemerkrankungen (2018) (0)
Die Interferon-Achse: autoinflammatorische Erkrankungen mit Kollagenose-Aspekten (2022) (0)
Faculty Opinions recommendation of ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisis-a EUSTAR analysis. (2020) (0)
[Cyclooxygenase 2 selective antirheumatic analgesics]. (2003) (0)
A Paper Patient-Based Flare Study in SLE (2015) (0)
Kriterien und Diagnose (2017) (0)
Pathogenese des systemischen Lupus erythematodes (2015) (0)
[Influence of therapy on risk of cancer in rheumatoid arthritis. Pathophysiological principles]. (2016) (0)
Die Interferon-Achse – autoinflammatorische Erkrankungen mit Kollagenose-Aspekten (2022) (0)
AB1197 Multiparametric analysis of connective tissue disease specific autoantibodies using a spot immunoassay (SERASPOT®ANA) (2018) (0)
Einfluss der Therapie auf das Krebsrisiko bei rheumatoider Arthritis (2016) (0)
Hohe Ziele – ACR/EULARRemissionskriterien für die rheumatoide Arthritis (2012) (0)
Recommendation 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus (2019) (0)
Stellenwert des Gray-Scale und Power Doppler Ultraschalls in der Gicht-Diagnostik: Vergleich mit Röntgen, Klinik und Laborparametern (2006) (0)
Sollte HCQ bei Dialysepflicht bei SLE eingesetzt werden? (2022) (0)
Leitbild der Rheumatologinnen und Rheumatologen in der Deutschen Gesellschaft für Rheumatologie e. V. (DGRh e. V.) (2020) (0)
Lupus erkennen und gezielt behandeln (2020) (0)
Arizona Immigration Law and Medical Practice (2010) (0)
Krankheitsaktivitätsmessung im klinischen Alltag: Kollagenosen (2009) (0)
Requirements for Including Novel Laboratory Tests into Classification Criteria. (2020) (0)
Die Zeitschrift für Rheumatologie dankt den Gutachtern 2011 (2023) (0)
FRI0136 Immune adsorption in highly active sle increases the risk of bacterial, but not of severe viral infections (2001) (0)
Die Zeitschrift für Rheumatologie dankt den Gutachtern 2015 (2016) (0)
Including uncommon cutaneous manifestations in systemic lupus erythematosus classification criteria. (2020) (0)
Moderne medikamentöse Therapie der interstitiellen Lungenerkrankung bei systemischer Sklerose (2021) (0)
Therapiestrategie bei systemischem Lupus erythematodes (2015) (0)
SAT0275 MAINTAINED BENEFIT IN HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB PLUS PREDNISONE TAPERING: RESULTS FROM THE OPEN-LABEL, LONG-TERM EXTENSION OF A PHASE 3 RANDOMIZED CONTROLLED TRIAL (2020) (0)
POS0002 IS THE RHEUMATOID ARTHRITIS IMPACT OF DISEASE SCORE (RAID) AN INFORMATIVE INSTRUMENT FOR OTHER INFLAMMATORY RHEUMATIC DISEASES? (2022) (0)
O8 Performance of the EULAR/ACR 2019 classification criteria for systemic lupus erythematosus in men, ethnicities, and early disease (2020) (0)
I5 Defining lupus: chances and challenges based on the EULAR/ACR criteria (2020) (0)
Correction to: Diagnosis and Classification of Systemic Lupus Erythematosus (2021) (0)
SS-56: a novel auto-antigen (2002) (0)
AB0512 Use of Nominal Group Technique To Facilitate Item Reduction for Sle Classification Criteria Development (2016) (0)
Lupustherapie in Bewegung (2015) (0)
erythaematosus core histones in human systemic lupus autoimmune responses to histone H 1 and Characterisation of cellular and humoral (2008) (0)
1301 Effect of attribution on external validation of the EULAR/ACR SLE classification criteria (2021) (0)
Neigung zu Autoimmunerkrankungen bei Diabetes - Rheumatologie und Diabetes - ein Crashkurs (2007) (0)
Performance of the EULAR/ACR 2019 Classifi cation Criteria for Systemic Lupus Erythematosus in Men, Diverse Ethnicities, and Early Disease (2019) (0)
Zum Jahresschluss: Vielen Dank! (2020) (0)
Autoreactive T cells to histone H1 and core histones in patients with systemic lupus erythematosus (2005) (0)
Homepage: www.kup.at/ mineralstoffwechsel Online-Datenbank mit Autoren- und Stichwortsuche Therapiemöglichkeiten nach Nichtansprechen von TNF-Blockern bei rheumatoider Arthritis (2017) (0)
Systemischer Lupus erythematodes – die Standards 2015 (2014) (0)
List of reviewers for 2007 (2007) (0)
POS0733 DISCORDANCE BETWEEN PATIENT GLOBAL ASSESSMENT AND PHYSICIAN GLOBAL ASSESSMENT OF DISEASE ACTIVITY IN THE MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS PROSPECTIVE OBSERVATIONAL COHORT STUDY (SPOCS) (2022) (0)
Diagnosis and Classification of Systemic Lupus Erythematosus (2021) (0)
Treat-to-Target bei systemischem Lupus erythematodes (2020) (0)
Maintained Benefit in Health-Related Quality of Life of Patients with Giant Cell Arteritis Treated with Tocilizumab Plus Prednisone Tapering : Results from the Open-Label, Long-Term Extension of a Phase 3 Randomized Controlled Trial (2019) (0)
[Systemic autoimmune diseases-fit for 2020!] (2019) (0)
POS0362 FACTORS ASSOCIATED WITH CHANGES IN COPING BEHAVIOUR IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS - A LONGITUDINAL STUDY OF THE LuLa COHORT (2022) (0)
[Rheumatology in German MD curricula]. (2020) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Martin Aringer?

Martin Aringer is affiliated with the following schools:

University of Vienna
TU Dresden
University of Innsbruck
Medical University of Vienna
University of Regensburg
University of Salzburg